nodes	percent_of_prediction	percent_of_DWPC	metapath
Celecoxib—hematologic cancer—Methylprednisolone—psoriatic arthritis	0.203	0.304	CpDpCtD
Celecoxib—colon cancer—Betamethasone—psoriatic arthritis	0.0915	0.137	CpDpCtD
Celecoxib—colon cancer—Dexamethasone—psoriatic arthritis	0.0915	0.137	CpDpCtD
Celecoxib—kidney cancer—Dexamethasone—psoriatic arthritis	0.0662	0.0991	CpDpCtD
Celecoxib—kidney cancer—Betamethasone—psoriatic arthritis	0.0662	0.0991	CpDpCtD
Celecoxib—ALB—Auranofin—psoriatic arthritis	0.0553	0.234	CbGbCtD
Celecoxib—prostate cancer—Betamethasone—psoriatic arthritis	0.0478	0.0716	CpDpCtD
Celecoxib—prostate cancer—Dexamethasone—psoriatic arthritis	0.0478	0.0716	CpDpCtD
Celecoxib—PTGS2—Triamcinolone—psoriatic arthritis	0.0349	0.148	CbGbCtD
Celecoxib—PTGS2—Betamethasone—psoriatic arthritis	0.03	0.127	CbGbCtD
Celecoxib—osteoarthritis—Prednisone—psoriatic arthritis	0.0269	0.0403	CpDpCtD
Celecoxib—osteoarthritis—Methylprednisolone—psoriatic arthritis	0.0269	0.0403	CpDpCtD
Celecoxib—ABCC4—Methotrexate—psoriatic arthritis	0.0238	0.101	CbGbCtD
Celecoxib—ALB—Prednisone—psoriatic arthritis	0.0176	0.0746	CbGbCtD
Celecoxib—PTGS2—Dexamethasone—psoriatic arthritis	0.0174	0.0739	CbGbCtD
Celecoxib—CYP3A4—Methylprednisolone—psoriatic arthritis	0.0091	0.0386	CbGbCtD
Celecoxib—ALB—Methotrexate—psoriatic arthritis	0.00883	0.0374	CbGbCtD
Celecoxib—CYP3A4—Triamcinolone—psoriatic arthritis	0.0069	0.0293	CbGbCtD
Celecoxib—CYP2C9—Dexamethasone—psoriatic arthritis	0.00592	0.0251	CbGbCtD
Celecoxib—CYP3A4—Betamethasone—psoriatic arthritis	0.00592	0.0251	CbGbCtD
Celecoxib—CYP3A4—Prednisolone—psoriatic arthritis	0.00584	0.0248	CbGbCtD
Celecoxib—CYP3A4—Prednisone—psoriatic arthritis	0.00552	0.0234	CbGbCtD
Celecoxib—CYP2D6—Dexamethasone—psoriatic arthritis	0.00542	0.023	CbGbCtD
Celecoxib—CYP3A4—Dexamethasone—psoriatic arthritis	0.00344	0.0146	CbGbCtD
Celecoxib—MAPK14—Atypical NF-kappaB pathway—REL—psoriatic arthritis	0.000576	0.0601	CbGpPWpGaD
Celecoxib—MAPK14—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—MEFV—psoriatic arthritis	0.000374	0.039	CbGpPWpGaD
Celecoxib—MAPK14—activated TAK1 mediates p38 MAPK activation—NOD2—psoriatic arthritis	0.000334	0.0348	CbGpPWpGaD
Celecoxib—PTGS2—Fluocinonide—Methylprednisolone—psoriatic arthritis	0.000329	0.159	CbGdCrCtD
Celecoxib—MAPK14—ATF-2 transcription factor network—IL23A—psoriatic arthritis	0.000327	0.0342	CbGpPWpGaD
Celecoxib—PTGS2—Fluocinonide—Betamethasone—psoriatic arthritis	0.000324	0.156	CbGdCrCtD
Celecoxib—PTGS2—Fluocinonide—Dexamethasone—psoriatic arthritis	0.000324	0.156	CbGdCrCtD
Celecoxib—PTGS2—Fluocinonide—Triamcinolone—psoriatic arthritis	0.000317	0.153	CbGdCrCtD
Celecoxib—MAPK14—IL4-mediated signaling events—LTA—psoriatic arthritis	0.000288	0.03	CbGpPWpGaD
Celecoxib—PDPK1—TCR Signaling Pathway—REL—psoriatic arthritis	0.00025	0.0261	CbGpPWpGaD
Celecoxib—PDPK1—B Cell Receptor Signaling Pathway—REL—psoriatic arthritis	0.000235	0.0246	CbGpPWpGaD
Celecoxib—PDPK1—Downstream TCR signaling—HLA-DRB1—psoriatic arthritis	0.000216	0.0225	CbGpPWpGaD
Celecoxib—PDPK1—TCR Signaling Pathway—IL17A—psoriatic arthritis	0.00021	0.022	CbGpPWpGaD
Celecoxib—MAPK14—NOD1/2 Signaling Pathway—NOD2—psoriatic arthritis	0.000206	0.0215	CbGpPWpGaD
Celecoxib—PTGS2—Fluticasone Propionate—Methylprednisolone—psoriatic arthritis	0.000199	0.0957	CbGdCrCtD
Celecoxib—MAPK14—Regulation of Androgen receptor activity—REL—psoriatic arthritis	0.000198	0.0207	CbGpPWpGaD
Celecoxib—MAPK14—Interferon type I signaling pathways—REL—psoriatic arthritis	0.000196	0.0204	CbGpPWpGaD
Celecoxib—PTGS2—Fluticasone Propionate—Betamethasone—psoriatic arthritis	0.000196	0.0942	CbGdCrCtD
Celecoxib—PTGS2—Fluticasone Propionate—Dexamethasone—psoriatic arthritis	0.000196	0.0942	CbGdCrCtD
Celecoxib—MAPK14—IL-1 signaling pathway—REL—psoriatic arthritis	0.000193	0.0201	CbGpPWpGaD
Celecoxib—PTGS2—Fluticasone Propionate—Triamcinolone—psoriatic arthritis	0.000191	0.0921	CbGdCrCtD
Celecoxib—PDPK1—TCR signaling—HLA-DRB1—psoriatic arthritis	0.000161	0.0168	CbGpPWpGaD
Celecoxib—PDPK1—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.000152	0.0159	CbGpPWpGaD
Celecoxib—MAPK14—Leptin signaling pathway—REL—psoriatic arthritis	0.00015	0.0157	CbGpPWpGaD
Celecoxib—PDPK1—TCR signaling in naïve CD4+ T cells—HLA-DRB1—psoriatic arthritis	0.000148	0.0154	CbGpPWpGaD
Celecoxib—PDPK1—Costimulation by the CD28 family—HLA-DRB1—psoriatic arthritis	0.000144	0.015	CbGpPWpGaD
Celecoxib—MAPK14—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—NOD2—psoriatic arthritis	0.000141	0.0147	CbGpPWpGaD
Celecoxib—MAPK14—IL12-mediated signaling events—IL12B—psoriatic arthritis	0.000141	0.0147	CbGpPWpGaD
Celecoxib—PTGS2—Overview of nanoparticle effects—CRP—psoriatic arthritis	0.000139	0.0145	CbGpPWpGaD
Celecoxib—PDPK1—B Cell Activation—REL—psoriatic arthritis	0.000135	0.0141	CbGpPWpGaD
Celecoxib—PDPK1—DAP12 interactions—HLA-C—psoriatic arthritis	0.000134	0.014	CbGpPWpGaD
Celecoxib—MAPK14—TCR Signaling Pathway—REL—psoriatic arthritis	0.00013	0.0136	CbGpPWpGaD
Celecoxib—MAPK14—MAP kinase activation in TLR cascade—NOD2—psoriatic arthritis	0.000129	0.0134	CbGpPWpGaD
Celecoxib—MAPK14—Glucocorticoid receptor regulatory network—IL13—psoriatic arthritis	0.000128	0.0134	CbGpPWpGaD
Celecoxib—MAPK14—B Cell Receptor Signaling Pathway—REL—psoriatic arthritis	0.000122	0.0128	CbGpPWpGaD
Celecoxib—PDPK1—CXCR4-mediated signaling events—HLA-DRB1—psoriatic arthritis	0.000122	0.0127	CbGpPWpGaD
Celecoxib—MAPK14—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriatic arthritis	0.000121	0.0127	CbGpPWpGaD
Celecoxib—CA9—HIF-1-alpha transcription factor network—NOS2—psoriatic arthritis	0.000121	0.0126	CbGpPWpGaD
Celecoxib—ORM1—vertebral column—psoriatic arthritis	0.000119	0.258	CbGeAlD
Celecoxib—MAPK14—TCR Signaling Pathway—IL17A—psoriatic arthritis	0.000109	0.0114	CbGpPWpGaD
Celecoxib—MAPK14—IL6-mediated signaling events—CRP—psoriatic arthritis	0.000105	0.011	CbGpPWpGaD
Celecoxib—MAPK14—TRAF6 Mediated Induction of proinflammatory cytokines—NOD2—psoriatic arthritis	0.000102	0.0106	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—MEFV—psoriatic arthritis	0.000102	0.0106	CbGpPWpGaD
Celecoxib—MAPK14—MyD88 cascade initiated on plasma membrane—NOD2—psoriatic arthritis	9.2e-05	0.0096	CbGpPWpGaD
Celecoxib—MAPK14—Toll-like Receptor Signaling Pathway—IL12B—psoriatic arthritis	9.2e-05	0.0096	CbGpPWpGaD
Celecoxib—MAPK14—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NOD2—psoriatic arthritis	9.12e-05	0.00951	CbGpPWpGaD
Celecoxib—MAPK14—MyD88 dependent cascade initiated on endosome—NOD2—psoriatic arthritis	8.95e-05	0.00934	CbGpPWpGaD
Celecoxib—MAPK14—Toll Like Receptor 9 (TLR9) Cascade—NOD2—psoriatic arthritis	8.64e-05	0.00901	CbGpPWpGaD
Celecoxib—MAPK14—MyD88:Mal cascade initiated on plasma membrane—NOD2—psoriatic arthritis	8.49e-05	0.00886	CbGpPWpGaD
Celecoxib—MAPK14—IL12-mediated signaling events—HLA-DRB1—psoriatic arthritis	8.28e-05	0.00864	CbGpPWpGaD
Celecoxib—MAPK14—MyD88-independent cascade—NOD2—psoriatic arthritis	8.15e-05	0.0085	CbGpPWpGaD
Celecoxib—PDPK1—Cardiac Hypertrophic Response—TNF—psoriatic arthritis	8.07e-05	0.00842	CbGpPWpGaD
Celecoxib—MAPK14—ATF-2 transcription factor network—NOS2—psoriatic arthritis	7.99e-05	0.00834	CbGpPWpGaD
Celecoxib—PDPK1—DAP12 interactions—HLA-B—psoriatic arthritis	7.92e-05	0.00826	CbGpPWpGaD
Celecoxib—MAPK14—IL12-mediated signaling events—NOS2—psoriatic arthritis	7.88e-05	0.00822	CbGpPWpGaD
Celecoxib—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriatic arthritis	7.75e-05	0.00809	CbGpPWpGaD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—psoriatic arthritis	7.42e-05	0.000884	CcSEcCtD
Celecoxib—Flushing—Prednisone—psoriatic arthritis	7.41e-05	0.000883	CcSEcCtD
Celecoxib—Stevens-Johnson syndrome—Methotrexate—psoriatic arthritis	7.37e-05	0.000878	CcSEcCtD
Celecoxib—MAPK14—Activated TLR4 signalling—NOD2—psoriatic arthritis	7.33e-05	0.00765	CbGpPWpGaD
Celecoxib—Dry mouth—Triamcinolone—psoriatic arthritis	7.32e-05	0.000872	CcSEcCtD
Celecoxib—MAPK14—AGE/RAGE pathway—NOS2—psoriatic arthritis	7.3e-05	0.00762	CbGpPWpGaD
Celecoxib—Angioedema—Betamethasone—psoriatic arthritis	7.29e-05	0.000869	CcSEcCtD
Celecoxib—Angioedema—Dexamethasone—psoriatic arthritis	7.29e-05	0.000869	CcSEcCtD
Celecoxib—Stomatitis—Methotrexate—psoriatic arthritis	7.24e-05	0.000863	CcSEcCtD
Celecoxib—Angiopathy—Prednisone—psoriatic arthritis	7.24e-05	0.000863	CcSEcCtD
Celecoxib—Conjunctivitis—Methotrexate—psoriatic arthritis	7.22e-05	0.000861	CcSEcCtD
Celecoxib—Confusional state—Methylprednisolone—psoriatic arthritis	7.22e-05	0.00086	CcSEcCtD
Celecoxib—MAPK14—Rac1/Pak1/p38/MMP-2 pathway—NOS2—psoriatic arthritis	7.22e-05	0.00753	CbGpPWpGaD
Celecoxib—Immune system disorder—Prednisone—psoriatic arthritis	7.21e-05	0.000859	CcSEcCtD
Celecoxib—MAPK14—Regulation of toll-like receptor signaling pathway—IL12B—psoriatic arthritis	7.18e-05	0.00749	CbGpPWpGaD
Celecoxib—Anaphylactic shock—Triamcinolone—psoriatic arthritis	7.18e-05	0.000855	CcSEcCtD
Celecoxib—Oedema—Triamcinolone—psoriatic arthritis	7.18e-05	0.000855	CcSEcCtD
Celecoxib—Vertigo—Dexamethasone—psoriatic arthritis	7.17e-05	0.000854	CcSEcCtD
Celecoxib—Vertigo—Betamethasone—psoriatic arthritis	7.17e-05	0.000854	CcSEcCtD
Celecoxib—PTGS2—skeletal joint—psoriatic arthritis	7.16e-05	0.155	CbGeAlD
Celecoxib—Anaphylactic shock—Methylprednisolone—psoriatic arthritis	7.16e-05	0.000853	CcSEcCtD
Celecoxib—Syncope—Dexamethasone—psoriatic arthritis	7.15e-05	0.000852	CcSEcCtD
Celecoxib—Syncope—Betamethasone—psoriatic arthritis	7.15e-05	0.000852	CcSEcCtD
Celecoxib—Arrhythmia—Prednisone—psoriatic arthritis	7.13e-05	0.00085	CcSEcCtD
Celecoxib—Infection—Triamcinolone—psoriatic arthritis	7.13e-05	0.000849	CcSEcCtD
Celecoxib—Infection—Methylprednisolone—psoriatic arthritis	7.11e-05	0.000848	CcSEcCtD
Celecoxib—Haematuria—Methotrexate—psoriatic arthritis	7.08e-05	0.000844	CcSEcCtD
Celecoxib—Shock—Triamcinolone—psoriatic arthritis	7.06e-05	0.000841	CcSEcCtD
Celecoxib—Insomnia—Prednisolone—psoriatic arthritis	7.06e-05	0.000841	CcSEcCtD
Celecoxib—Alopecia—Prednisone—psoriatic arthritis	7.05e-05	0.00084	CcSEcCtD
Celecoxib—Shock—Methylprednisolone—psoriatic arthritis	7.04e-05	0.000839	CcSEcCtD
Celecoxib—Hepatobiliary disease—Methotrexate—psoriatic arthritis	7.03e-05	0.000837	CcSEcCtD
Celecoxib—Nervous system disorder—Methylprednisolone—psoriatic arthritis	7.02e-05	0.000837	CcSEcCtD
Celecoxib—Loss of consciousness—Dexamethasone—psoriatic arthritis	7.01e-05	0.000835	CcSEcCtD
Celecoxib—Loss of consciousness—Betamethasone—psoriatic arthritis	7.01e-05	0.000835	CcSEcCtD
Celecoxib—Epistaxis—Methotrexate—psoriatic arthritis	7.01e-05	0.000835	CcSEcCtD
Celecoxib—Paraesthesia—Prednisolone—psoriatic arthritis	7.01e-05	0.000835	CcSEcCtD
Celecoxib—Tachycardia—Triamcinolone—psoriatic arthritis	7e-05	0.000834	CcSEcCtD
Celecoxib—Mental disorder—Prednisone—psoriatic arthritis	6.99e-05	0.000833	CcSEcCtD
Celecoxib—Tachycardia—Methylprednisolone—psoriatic arthritis	6.99e-05	0.000833	CcSEcCtD
Celecoxib—Skin disorder—Methylprednisolone—psoriatic arthritis	6.95e-05	0.000829	CcSEcCtD
Celecoxib—Hyperhidrosis—Triamcinolone—psoriatic arthritis	6.94e-05	0.000827	CcSEcCtD
Celecoxib—Agranulocytosis—Methotrexate—psoriatic arthritis	6.93e-05	0.000826	CcSEcCtD
Celecoxib—Hyperhidrosis—Methylprednisolone—psoriatic arthritis	6.92e-05	0.000825	CcSEcCtD
Celecoxib—MAPK14—Toll Like Receptor 4 (TLR4) Cascade—NOD2—psoriatic arthritis	6.89e-05	0.00719	CbGpPWpGaD
Celecoxib—Hypertension—Dexamethasone—psoriatic arthritis	6.89e-05	0.000821	CcSEcCtD
Celecoxib—Hypertension—Betamethasone—psoriatic arthritis	6.89e-05	0.000821	CcSEcCtD
Celecoxib—Myalgia—Betamethasone—psoriatic arthritis	6.79e-05	0.000809	CcSEcCtD
Celecoxib—Myalgia—Dexamethasone—psoriatic arthritis	6.79e-05	0.000809	CcSEcCtD
Celecoxib—Anxiety—Dexamethasone—psoriatic arthritis	6.77e-05	0.000806	CcSEcCtD
Celecoxib—Anxiety—Betamethasone—psoriatic arthritis	6.77e-05	0.000806	CcSEcCtD
Celecoxib—Haemoglobin—Methotrexate—psoriatic arthritis	6.7e-05	0.000799	CcSEcCtD
Celecoxib—Haemorrhage—Methotrexate—psoriatic arthritis	6.67e-05	0.000795	CcSEcCtD
Celecoxib—Hepatitis—Methotrexate—psoriatic arthritis	6.67e-05	0.000795	CcSEcCtD
Celecoxib—Pharyngitis—Methotrexate—psoriatic arthritis	6.62e-05	0.000789	CcSEcCtD
Celecoxib—Urinary tract disorder—Methotrexate—psoriatic arthritis	6.59e-05	0.000785	CcSEcCtD
Celecoxib—Vision blurred—Prednisone—psoriatic arthritis	6.55e-05	0.00078	CcSEcCtD
Celecoxib—Urethral disorder—Methotrexate—psoriatic arthritis	6.54e-05	0.000779	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Triamcinolone—psoriatic arthritis	6.54e-05	0.000779	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Methylprednisolone—psoriatic arthritis	6.52e-05	0.000777	CcSEcCtD
Celecoxib—Oedema—Dexamethasone—psoriatic arthritis	6.51e-05	0.000776	CcSEcCtD
Celecoxib—Anaphylactic shock—Dexamethasone—psoriatic arthritis	6.51e-05	0.000776	CcSEcCtD
Celecoxib—Anaphylactic shock—Betamethasone—psoriatic arthritis	6.51e-05	0.000776	CcSEcCtD
Celecoxib—Oedema—Betamethasone—psoriatic arthritis	6.51e-05	0.000776	CcSEcCtD
Celecoxib—Insomnia—Triamcinolone—psoriatic arthritis	6.49e-05	0.000773	CcSEcCtD
Celecoxib—Insomnia—Methylprednisolone—psoriatic arthritis	6.48e-05	0.000772	CcSEcCtD
Celecoxib—MAPK14—Monoamine Transport—TNF—psoriatic arthritis	6.47e-05	0.00675	CbGpPWpGaD
Celecoxib—Infection—Betamethasone—psoriatic arthritis	6.47e-05	0.000771	CcSEcCtD
Celecoxib—Infection—Dexamethasone—psoriatic arthritis	6.47e-05	0.000771	CcSEcCtD
Celecoxib—Paraesthesia—Triamcinolone—psoriatic arthritis	6.44e-05	0.000768	CcSEcCtD
Celecoxib—Feeling abnormal—Prednisolone—psoriatic arthritis	6.43e-05	0.000766	CcSEcCtD
Celecoxib—Paraesthesia—Methylprednisolone—psoriatic arthritis	6.43e-05	0.000766	CcSEcCtD
Celecoxib—Anaemia—Prednisone—psoriatic arthritis	6.42e-05	0.000765	CcSEcCtD
Celecoxib—Shock—Betamethasone—psoriatic arthritis	6.41e-05	0.000763	CcSEcCtD
Celecoxib—Shock—Dexamethasone—psoriatic arthritis	6.41e-05	0.000763	CcSEcCtD
Celecoxib—Dyspnoea—Triamcinolone—psoriatic arthritis	6.4e-05	0.000762	CcSEcCtD
Celecoxib—MAPK14—Platelet homeostasis—NOS2—psoriatic arthritis	6.39e-05	0.00667	CbGpPWpGaD
Celecoxib—Nervous system disorder—Dexamethasone—psoriatic arthritis	6.38e-05	0.000761	CcSEcCtD
Celecoxib—Nervous system disorder—Betamethasone—psoriatic arthritis	6.38e-05	0.000761	CcSEcCtD
Celecoxib—Thrombocytopenia—Betamethasone—psoriatic arthritis	6.37e-05	0.00076	CcSEcCtD
Celecoxib—Thrombocytopenia—Dexamethasone—psoriatic arthritis	6.37e-05	0.00076	CcSEcCtD
Celecoxib—Tachycardia—Dexamethasone—psoriatic arthritis	6.35e-05	0.000757	CcSEcCtD
Celecoxib—Tachycardia—Betamethasone—psoriatic arthritis	6.35e-05	0.000757	CcSEcCtD
Celecoxib—Angioedema—Prednisone—psoriatic arthritis	6.35e-05	0.000756	CcSEcCtD
Celecoxib—Dyspepsia—Triamcinolone—psoriatic arthritis	6.32e-05	0.000753	CcSEcCtD
Celecoxib—Erythema multiforme—Methotrexate—psoriatic arthritis	6.31e-05	0.000751	CcSEcCtD
Celecoxib—Dyspepsia—Methylprednisolone—psoriatic arthritis	6.3e-05	0.000751	CcSEcCtD
Celecoxib—Hyperhidrosis—Dexamethasone—psoriatic arthritis	6.29e-05	0.00075	CcSEcCtD
Celecoxib—Hyperhidrosis—Betamethasone—psoriatic arthritis	6.29e-05	0.00075	CcSEcCtD
Celecoxib—PTGS2—Overview of nanoparticle effects—TNF—psoriatic arthritis	6.27e-05	0.00654	CbGpPWpGaD
Celecoxib—Vertigo—Prednisone—psoriatic arthritis	6.24e-05	0.000744	CcSEcCtD
Celecoxib—Eye disorder—Methotrexate—psoriatic arthritis	6.23e-05	0.000743	CcSEcCtD
Celecoxib—Syncope—Prednisone—psoriatic arthritis	6.23e-05	0.000742	CcSEcCtD
Celecoxib—Tinnitus—Methotrexate—psoriatic arthritis	6.22e-05	0.000741	CcSEcCtD
Celecoxib—Anorexia—Dexamethasone—psoriatic arthritis	6.21e-05	0.000739	CcSEcCtD
Celecoxib—Anorexia—Betamethasone—psoriatic arthritis	6.21e-05	0.000739	CcSEcCtD
Celecoxib—Urticaria—Prednisolone—psoriatic arthritis	6.2e-05	0.000739	CcSEcCtD
Celecoxib—Cardiac disorder—Methotrexate—psoriatic arthritis	6.19e-05	0.000738	CcSEcCtD
Celecoxib—Fatigue—Triamcinolone—psoriatic arthritis	6.19e-05	0.000737	CcSEcCtD
Celecoxib—Fatigue—Methylprednisolone—psoriatic arthritis	6.17e-05	0.000736	CcSEcCtD
Celecoxib—MAPK14—Toll-Like Receptors Cascades—NOD2—psoriatic arthritis	6.14e-05	0.00641	CbGpPWpGaD
Celecoxib—Loss of consciousness—Prednisone—psoriatic arthritis	6.11e-05	0.000728	CcSEcCtD
Celecoxib—Angiopathy—Methotrexate—psoriatic arthritis	6.05e-05	0.000721	CcSEcCtD
Celecoxib—Immune system disorder—Methotrexate—psoriatic arthritis	6.02e-05	0.000718	CcSEcCtD
Celecoxib—Mediastinal disorder—Methotrexate—psoriatic arthritis	6.01e-05	0.000716	CcSEcCtD
Celecoxib—Hypertension—Prednisone—psoriatic arthritis	6e-05	0.000715	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Betamethasone—psoriatic arthritis	5.93e-05	0.000707	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Dexamethasone—psoriatic arthritis	5.93e-05	0.000707	CcSEcCtD
Celecoxib—PDPK1—Immune System—MEFV—psoriatic arthritis	5.92e-05	0.00618	CbGpPWpGaD
Celecoxib—Myalgia—Prednisone—psoriatic arthritis	5.91e-05	0.000705	CcSEcCtD
Celecoxib—Arthralgia—Prednisone—psoriatic arthritis	5.91e-05	0.000705	CcSEcCtD
Celecoxib—Feeling abnormal—Triamcinolone—psoriatic arthritis	5.91e-05	0.000705	CcSEcCtD
Celecoxib—Feeling abnormal—Methylprednisolone—psoriatic arthritis	5.9e-05	0.000703	CcSEcCtD
Celecoxib—Anxiety—Prednisone—psoriatic arthritis	5.89e-05	0.000702	CcSEcCtD
Celecoxib—Alopecia—Methotrexate—psoriatic arthritis	5.89e-05	0.000702	CcSEcCtD
Celecoxib—Insomnia—Betamethasone—psoriatic arthritis	5.89e-05	0.000702	CcSEcCtD
Celecoxib—Insomnia—Dexamethasone—psoriatic arthritis	5.89e-05	0.000702	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	5.87e-05	0.0007	CcSEcCtD
Celecoxib—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	5.85e-05	0.000698	CcSEcCtD
Celecoxib—Paraesthesia—Betamethasone—psoriatic arthritis	5.85e-05	0.000697	CcSEcCtD
Celecoxib—Paraesthesia—Dexamethasone—psoriatic arthritis	5.85e-05	0.000697	CcSEcCtD
Celecoxib—Mental disorder—Methotrexate—psoriatic arthritis	5.84e-05	0.000696	CcSEcCtD
Celecoxib—PDPK1—MicroRNAs in cardiomyocyte hypertrophy—TNF—psoriatic arthritis	5.75e-05	0.006	CbGpPWpGaD
Celecoxib—Hypersensitivity—Prednisolone—psoriatic arthritis	5.75e-05	0.000685	CcSEcCtD
Celecoxib—Dyspepsia—Dexamethasone—psoriatic arthritis	5.73e-05	0.000683	CcSEcCtD
Celecoxib—Dyspepsia—Betamethasone—psoriatic arthritis	5.73e-05	0.000683	CcSEcCtD
Celecoxib—Urticaria—Triamcinolone—psoriatic arthritis	5.7e-05	0.000679	CcSEcCtD
Celecoxib—Urticaria—Methylprednisolone—psoriatic arthritis	5.69e-05	0.000678	CcSEcCtD
Celecoxib—Dysgeusia—Methotrexate—psoriatic arthritis	5.69e-05	0.000677	CcSEcCtD
Celecoxib—Body temperature increased—Triamcinolone—psoriatic arthritis	5.67e-05	0.000676	CcSEcCtD
Celecoxib—Oedema—Prednisone—psoriatic arthritis	5.67e-05	0.000676	CcSEcCtD
Celecoxib—Anaphylactic shock—Prednisone—psoriatic arthritis	5.67e-05	0.000676	CcSEcCtD
Celecoxib—Abdominal pain—Methylprednisolone—psoriatic arthritis	5.66e-05	0.000674	CcSEcCtD
Celecoxib—Decreased appetite—Dexamethasone—psoriatic arthritis	5.66e-05	0.000674	CcSEcCtD
Celecoxib—Decreased appetite—Betamethasone—psoriatic arthritis	5.66e-05	0.000674	CcSEcCtD
Celecoxib—MAPK14—Amyotrophic lateral sclerosis (ALS)—TNF—psoriatic arthritis	5.64e-05	0.00588	CbGpPWpGaD
Celecoxib—Infection—Prednisone—psoriatic arthritis	5.63e-05	0.000671	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	5.62e-05	0.00067	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	5.62e-05	0.00067	CcSEcCtD
Celecoxib—Back pain—Methotrexate—psoriatic arthritis	5.62e-05	0.000669	CcSEcCtD
Celecoxib—Fatigue—Betamethasone—psoriatic arthritis	5.61e-05	0.000669	CcSEcCtD
Celecoxib—Fatigue—Dexamethasone—psoriatic arthritis	5.61e-05	0.000669	CcSEcCtD
Celecoxib—Shock—Prednisone—psoriatic arthritis	5.58e-05	0.000665	CcSEcCtD
Celecoxib—Nervous system disorder—Prednisone—psoriatic arthritis	5.56e-05	0.000663	CcSEcCtD
Celecoxib—Tachycardia—Prednisone—psoriatic arthritis	5.53e-05	0.000659	CcSEcCtD
Celecoxib—Skin disorder—Prednisone—psoriatic arthritis	5.51e-05	0.000656	CcSEcCtD
Celecoxib—Hyperhidrosis—Prednisone—psoriatic arthritis	5.48e-05	0.000653	CcSEcCtD
Celecoxib—Vision blurred—Methotrexate—psoriatic arthritis	5.47e-05	0.000652	CcSEcCtD
Celecoxib—PTGS2—synovial membrane of synovial joint—psoriatic arthritis	5.44e-05	0.118	CbGeAlD
Celecoxib—PDPK1—Adaptive Immune System—REL—psoriatic arthritis	5.43e-05	0.00567	CbGpPWpGaD
Celecoxib—Anorexia—Prednisone—psoriatic arthritis	5.4e-05	0.000644	CcSEcCtD
Celecoxib—Anaemia—Methotrexate—psoriatic arthritis	5.37e-05	0.000639	CcSEcCtD
Celecoxib—Feeling abnormal—Dexamethasone—psoriatic arthritis	5.36e-05	0.000639	CcSEcCtD
Celecoxib—Feeling abnormal—Betamethasone—psoriatic arthritis	5.36e-05	0.000639	CcSEcCtD
Celecoxib—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	5.32e-05	0.000634	CcSEcCtD
Celecoxib—Gastrointestinal pain—Betamethasone—psoriatic arthritis	5.32e-05	0.000634	CcSEcCtD
Celecoxib—Hypersensitivity—Triamcinolone—psoriatic arthritis	5.29e-05	0.00063	CcSEcCtD
Celecoxib—MAPK14—Innate Immune System—MEFV—psoriatic arthritis	5.28e-05	0.00551	CbGpPWpGaD
Celecoxib—Hypersensitivity—Methylprednisolone—psoriatic arthritis	5.27e-05	0.000629	CcSEcCtD
Celecoxib—Vertigo—Methotrexate—psoriatic arthritis	5.22e-05	0.000622	CcSEcCtD
Celecoxib—MAPK14—TWEAK Signaling Pathway—TNF—psoriatic arthritis	5.21e-05	0.00543	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—HLA-C—psoriatic arthritis	5.2e-05	0.00543	CbGpPWpGaD
Celecoxib—Leukopenia—Methotrexate—psoriatic arthritis	5.2e-05	0.000619	CcSEcCtD
Celecoxib—Urticaria—Betamethasone—psoriatic arthritis	5.17e-05	0.000616	CcSEcCtD
Celecoxib—Urticaria—Dexamethasone—psoriatic arthritis	5.17e-05	0.000616	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Prednisone—psoriatic arthritis	5.17e-05	0.000616	CcSEcCtD
Celecoxib—Dizziness—Prednisolone—psoriatic arthritis	5.16e-05	0.000615	CcSEcCtD
Celecoxib—Asthenia—Triamcinolone—psoriatic arthritis	5.15e-05	0.000613	CcSEcCtD
Celecoxib—Abdominal pain—Betamethasone—psoriatic arthritis	5.15e-05	0.000613	CcSEcCtD
Celecoxib—Body temperature increased—Betamethasone—psoriatic arthritis	5.15e-05	0.000613	CcSEcCtD
Celecoxib—Body temperature increased—Dexamethasone—psoriatic arthritis	5.15e-05	0.000613	CcSEcCtD
Celecoxib—Abdominal pain—Dexamethasone—psoriatic arthritis	5.15e-05	0.000613	CcSEcCtD
Celecoxib—Asthenia—Methylprednisolone—psoriatic arthritis	5.14e-05	0.000612	CcSEcCtD
Celecoxib—Insomnia—Prednisone—psoriatic arthritis	5.13e-05	0.000611	CcSEcCtD
Celecoxib—Paraesthesia—Prednisone—psoriatic arthritis	5.09e-05	0.000607	CcSEcCtD
Celecoxib—ALB—Vitamin B12 Metabolism—CRP—psoriatic arthritis	5.09e-05	0.00531	CbGpPWpGaD
Celecoxib—Pruritus—Triamcinolone—psoriatic arthritis	5.08e-05	0.000605	CcSEcCtD
Celecoxib—Cough—Methotrexate—psoriatic arthritis	5.07e-05	0.000604	CcSEcCtD
Celecoxib—Pruritus—Methylprednisolone—psoriatic arthritis	5.07e-05	0.000604	CcSEcCtD
Celecoxib—PDPK1—Adaptive Immune System—HLA-C—psoriatic arthritis	5e-05	0.00521	CbGpPWpGaD
Celecoxib—Dyspepsia—Prednisone—psoriatic arthritis	4.99e-05	0.000595	CcSEcCtD
Celecoxib—Arthralgia—Methotrexate—psoriatic arthritis	4.94e-05	0.000589	CcSEcCtD
Celecoxib—Chest pain—Methotrexate—psoriatic arthritis	4.94e-05	0.000589	CcSEcCtD
Celecoxib—Myalgia—Methotrexate—psoriatic arthritis	4.94e-05	0.000589	CcSEcCtD
Celecoxib—Decreased appetite—Prednisone—psoriatic arthritis	4.93e-05	0.000587	CcSEcCtD
Celecoxib—Rash—Prednisolone—psoriatic arthritis	4.92e-05	0.000586	CcSEcCtD
Celecoxib—Dermatitis—Prednisolone—psoriatic arthritis	4.91e-05	0.000586	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	4.91e-05	0.000585	CcSEcCtD
Celecoxib—Diarrhoea—Methylprednisolone—psoriatic arthritis	4.9e-05	0.000584	CcSEcCtD
Celecoxib—Fatigue—Prednisone—psoriatic arthritis	4.89e-05	0.000582	CcSEcCtD
Celecoxib—Headache—Prednisolone—psoriatic arthritis	4.89e-05	0.000582	CcSEcCtD
Celecoxib—Constipation—Prednisone—psoriatic arthritis	4.85e-05	0.000578	CcSEcCtD
Celecoxib—Confusional state—Methotrexate—psoriatic arthritis	4.78e-05	0.000569	CcSEcCtD
Celecoxib—Dizziness—Triamcinolone—psoriatic arthritis	4.74e-05	0.000565	CcSEcCtD
Celecoxib—Anaphylactic shock—Methotrexate—psoriatic arthritis	4.74e-05	0.000565	CcSEcCtD
Celecoxib—Dizziness—Methylprednisolone—psoriatic arthritis	4.73e-05	0.000564	CcSEcCtD
Celecoxib—Infection—Methotrexate—psoriatic arthritis	4.71e-05	0.000561	CcSEcCtD
Celecoxib—Feeling abnormal—Prednisone—psoriatic arthritis	4.67e-05	0.000557	CcSEcCtD
Celecoxib—Asthenia—Dexamethasone—psoriatic arthritis	4.67e-05	0.000557	CcSEcCtD
Celecoxib—Asthenia—Betamethasone—psoriatic arthritis	4.67e-05	0.000557	CcSEcCtD
Celecoxib—Nervous system disorder—Methotrexate—psoriatic arthritis	4.65e-05	0.000554	CcSEcCtD
Celecoxib—Thrombocytopenia—Methotrexate—psoriatic arthritis	4.64e-05	0.000553	CcSEcCtD
Celecoxib—Gastrointestinal pain—Prednisone—psoriatic arthritis	4.64e-05	0.000552	CcSEcCtD
Celecoxib—Nausea—Prednisolone—psoriatic arthritis	4.63e-05	0.000552	CcSEcCtD
Celecoxib—Pruritus—Dexamethasone—psoriatic arthritis	4.61e-05	0.000549	CcSEcCtD
Celecoxib—Pruritus—Betamethasone—psoriatic arthritis	4.61e-05	0.000549	CcSEcCtD
Celecoxib—Skin disorder—Methotrexate—psoriatic arthritis	4.6e-05	0.000548	CcSEcCtD
Celecoxib—Hyperhidrosis—Methotrexate—psoriatic arthritis	4.58e-05	0.000546	CcSEcCtD
Celecoxib—Vomiting—Triamcinolone—psoriatic arthritis	4.56e-05	0.000544	CcSEcCtD
Celecoxib—Vomiting—Methylprednisolone—psoriatic arthritis	4.55e-05	0.000542	CcSEcCtD
Celecoxib—MAPK14—Angiopoietin receptor Tie2-mediated signaling—TNF—psoriatic arthritis	4.53e-05	0.00472	CbGpPWpGaD
Celecoxib—Rash—Triamcinolone—psoriatic arthritis	4.52e-05	0.000539	CcSEcCtD
Celecoxib—Dermatitis—Triamcinolone—psoriatic arthritis	4.52e-05	0.000539	CcSEcCtD
Celecoxib—Anorexia—Methotrexate—psoriatic arthritis	4.52e-05	0.000538	CcSEcCtD
Celecoxib—Rash—Methylprednisolone—psoriatic arthritis	4.51e-05	0.000538	CcSEcCtD
Celecoxib—Dermatitis—Methylprednisolone—psoriatic arthritis	4.51e-05	0.000537	CcSEcCtD
Celecoxib—Urticaria—Prednisone—psoriatic arthritis	4.5e-05	0.000537	CcSEcCtD
Celecoxib—Headache—Triamcinolone—psoriatic arthritis	4.49e-05	0.000536	CcSEcCtD
Celecoxib—Headache—Methylprednisolone—psoriatic arthritis	4.48e-05	0.000534	CcSEcCtD
Celecoxib—Abdominal pain—Prednisone—psoriatic arthritis	4.48e-05	0.000534	CcSEcCtD
Celecoxib—Body temperature increased—Prednisone—psoriatic arthritis	4.48e-05	0.000534	CcSEcCtD
Celecoxib—Diarrhoea—Dexamethasone—psoriatic arthritis	4.45e-05	0.000531	CcSEcCtD
Celecoxib—Diarrhoea—Betamethasone—psoriatic arthritis	4.45e-05	0.000531	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Methotrexate—psoriatic arthritis	4.32e-05	0.000514	CcSEcCtD
Celecoxib—Dizziness—Betamethasone—psoriatic arthritis	4.31e-05	0.000513	CcSEcCtD
Celecoxib—Dizziness—Dexamethasone—psoriatic arthritis	4.31e-05	0.000513	CcSEcCtD
Celecoxib—Insomnia—Methotrexate—psoriatic arthritis	4.29e-05	0.000511	CcSEcCtD
Celecoxib—Nausea—Triamcinolone—psoriatic arthritis	4.26e-05	0.000508	CcSEcCtD
Celecoxib—Paraesthesia—Methotrexate—psoriatic arthritis	4.25e-05	0.000507	CcSEcCtD
Celecoxib—Nausea—Methylprednisolone—psoriatic arthritis	4.25e-05	0.000507	CcSEcCtD
Celecoxib—Dyspnoea—Methotrexate—psoriatic arthritis	4.22e-05	0.000503	CcSEcCtD
Celecoxib—Somnolence—Methotrexate—psoriatic arthritis	4.21e-05	0.000502	CcSEcCtD
Celecoxib—MAPK14—Cardiac Hypertrophic Response—TNF—psoriatic arthritis	4.2e-05	0.00438	CbGpPWpGaD
Celecoxib—Hypersensitivity—Prednisone—psoriatic arthritis	4.18e-05	0.000498	CcSEcCtD
Celecoxib—Dyspepsia—Methotrexate—psoriatic arthritis	4.17e-05	0.000497	CcSEcCtD
Celecoxib—ALB—Folate Metabolism—CRP—psoriatic arthritis	4.14e-05	0.00432	CbGpPWpGaD
Celecoxib—Vomiting—Dexamethasone—psoriatic arthritis	4.14e-05	0.000493	CcSEcCtD
Celecoxib—Vomiting—Betamethasone—psoriatic arthritis	4.14e-05	0.000493	CcSEcCtD
Celecoxib—Decreased appetite—Methotrexate—psoriatic arthritis	4.12e-05	0.000491	CcSEcCtD
Celecoxib—Rash—Dexamethasone—psoriatic arthritis	4.1e-05	0.000489	CcSEcCtD
Celecoxib—Rash—Betamethasone—psoriatic arthritis	4.1e-05	0.000489	CcSEcCtD
Celecoxib—Dermatitis—Dexamethasone—psoriatic arthritis	4.1e-05	0.000489	CcSEcCtD
Celecoxib—Dermatitis—Betamethasone—psoriatic arthritis	4.1e-05	0.000489	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	4.09e-05	0.000487	CcSEcCtD
Celecoxib—Fatigue—Methotrexate—psoriatic arthritis	4.09e-05	0.000487	CcSEcCtD
Celecoxib—Headache—Dexamethasone—psoriatic arthritis	4.08e-05	0.000486	CcSEcCtD
Celecoxib—Headache—Betamethasone—psoriatic arthritis	4.08e-05	0.000486	CcSEcCtD
Celecoxib—Asthenia—Prednisone—psoriatic arthritis	4.07e-05	0.000485	CcSEcCtD
Celecoxib—PTGS2—Selenium Micronutrient Network—CRP—psoriatic arthritis	4.07e-05	0.00424	CbGpPWpGaD
Celecoxib—Pruritus—Prednisone—psoriatic arthritis	4.01e-05	0.000478	CcSEcCtD
Celecoxib—Feeling abnormal—Methotrexate—psoriatic arthritis	3.9e-05	0.000465	CcSEcCtD
Celecoxib—Diarrhoea—Prednisone—psoriatic arthritis	3.88e-05	0.000462	CcSEcCtD
Celecoxib—Gastrointestinal pain—Methotrexate—psoriatic arthritis	3.87e-05	0.000462	CcSEcCtD
Celecoxib—Nausea—Dexamethasone—psoriatic arthritis	3.87e-05	0.000461	CcSEcCtD
Celecoxib—Nausea—Betamethasone—psoriatic arthritis	3.87e-05	0.000461	CcSEcCtD
Celecoxib—PDPK1—Innate Immune System—NOD2—psoriatic arthritis	3.83e-05	0.00399	CbGpPWpGaD
Celecoxib—Urticaria—Methotrexate—psoriatic arthritis	3.76e-05	0.000449	CcSEcCtD
Celecoxib—MAPK14—skin of body—psoriatic arthritis	3.76e-05	0.0816	CbGeAlD
Celecoxib—Dizziness—Prednisone—psoriatic arthritis	3.75e-05	0.000447	CcSEcCtD
Celecoxib—Abdominal pain—Methotrexate—psoriatic arthritis	3.75e-05	0.000446	CcSEcCtD
Celecoxib—Body temperature increased—Methotrexate—psoriatic arthritis	3.75e-05	0.000446	CcSEcCtD
Celecoxib—Vomiting—Prednisone—psoriatic arthritis	3.6e-05	0.00043	CcSEcCtD
Celecoxib—Rash—Prednisone—psoriatic arthritis	3.57e-05	0.000426	CcSEcCtD
Celecoxib—Dermatitis—Prednisone—psoriatic arthritis	3.57e-05	0.000426	CcSEcCtD
Celecoxib—Headache—Prednisone—psoriatic arthritis	3.55e-05	0.000423	CcSEcCtD
Celecoxib—Hypersensitivity—Methotrexate—psoriatic arthritis	3.49e-05	0.000416	CcSEcCtD
Celecoxib—Asthenia—Methotrexate—psoriatic arthritis	3.4e-05	0.000405	CcSEcCtD
Celecoxib—Nausea—Prednisone—psoriatic arthritis	3.37e-05	0.000401	CcSEcCtD
Celecoxib—Pruritus—Methotrexate—psoriatic arthritis	3.35e-05	0.000399	CcSEcCtD
Celecoxib—PDPK1—Immune System—REL—psoriatic arthritis	3.29e-05	0.00344	CbGpPWpGaD
Celecoxib—ALB—Selenium Micronutrient Network—CRP—psoriatic arthritis	3.29e-05	0.00343	CbGpPWpGaD
Celecoxib—Diarrhoea—Methotrexate—psoriatic arthritis	3.24e-05	0.000386	CcSEcCtD
Celecoxib—Dizziness—Methotrexate—psoriatic arthritis	3.13e-05	0.000373	CcSEcCtD
Celecoxib—PTGS2—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	3.09e-05	0.00323	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—HLA-B—psoriatic arthritis	3.08e-05	0.00321	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—MEFV—psoriatic arthritis	3.08e-05	0.00321	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—HLA-C—psoriatic arthritis	3.03e-05	0.00316	CbGpPWpGaD
Celecoxib—Vomiting—Methotrexate—psoriatic arthritis	3.01e-05	0.000359	CcSEcCtD
Celecoxib—MAPK14—MicroRNAs in cardiomyocyte hypertrophy—TNF—psoriatic arthritis	2.99e-05	0.00312	CbGpPWpGaD
Celecoxib—Rash—Methotrexate—psoriatic arthritis	2.99e-05	0.000356	CcSEcCtD
Celecoxib—Dermatitis—Methotrexate—psoriatic arthritis	2.98e-05	0.000356	CcSEcCtD
Celecoxib—Headache—Methotrexate—psoriatic arthritis	2.97e-05	0.000354	CcSEcCtD
Celecoxib—PDPK1—Adaptive Immune System—HLA-B—psoriatic arthritis	2.96e-05	0.00308	CbGpPWpGaD
Celecoxib—CA9—tendon—psoriatic arthritis	2.93e-05	0.0637	CbGeAlD
Celecoxib—PTGS2—Spinal Cord Injury—NOS2—psoriatic arthritis	2.93e-05	0.00306	CbGpPWpGaD
Celecoxib—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriatic arthritis	2.89e-05	0.00302	CbGpPWpGaD
Celecoxib—MAPK14—tendon—psoriatic arthritis	2.86e-05	0.0621	CbGeAlD
Celecoxib—Nausea—Methotrexate—psoriatic arthritis	2.81e-05	0.000335	CcSEcCtD
Celecoxib—CA14—tendon—psoriatic arthritis	2.78e-05	0.0604	CbGeAlD
Celecoxib—PDPK1—Hemostasis—NOS2—psoriatic arthritis	2.76e-05	0.00287	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—CRP—psoriatic arthritis	2.72e-05	0.00284	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—HLA-C—psoriatic arthritis	2.7e-05	0.00282	CbGpPWpGaD
Celecoxib—MAPK14—Toll-like Receptor Signaling Pathway—TNF—psoriatic arthritis	2.56e-05	0.00267	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	2.5e-05	0.00261	CbGpPWpGaD
Celecoxib—ALB—Vitamin B12 Metabolism—TNF—psoriatic arthritis	2.3e-05	0.0024	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—NOD2—psoriatic arthritis	2.23e-05	0.00233	CbGpPWpGaD
Celecoxib—MAPK14—Regulation of toll-like receptor signaling pathway—TNF—psoriatic arthritis	2e-05	0.00208	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—NOD2—psoriatic arthritis	1.99e-05	0.00207	CbGpPWpGaD
Celecoxib—CA5B—tendon—psoriatic arthritis	1.95e-05	0.0423	CbGeAlD
Celecoxib—ALB—Folate Metabolism—TNF—psoriatic arthritis	1.87e-05	0.00196	CbGpPWpGaD
Celecoxib—PTGS2—Selenium Micronutrient Network—TNF—psoriatic arthritis	1.84e-05	0.00192	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—HLA-B—psoriatic arthritis	1.79e-05	0.00187	CbGpPWpGaD
Celecoxib—MAPK14—MAPK Signaling Pathway—TNF—psoriatic arthritis	1.72e-05	0.00179	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—REL—psoriatic arthritis	1.71e-05	0.00179	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—NOS2—psoriatic arthritis	1.64e-05	0.00171	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—HLA-B—psoriatic arthritis	1.6e-05	0.00167	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—CRP—psoriatic arthritis	1.58e-05	0.00165	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—HLA-C—psoriatic arthritis	1.58e-05	0.00164	CbGpPWpGaD
Celecoxib—MAPK14—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	1.55e-05	0.00162	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—HLA-DRB1—psoriatic arthritis	1.52e-05	0.00158	CbGpPWpGaD
Celecoxib—ALB—Selenium Micronutrient Network—TNF—psoriatic arthritis	1.49e-05	0.00155	CbGpPWpGaD
Celecoxib—CA2—skin of body—psoriatic arthritis	1.46e-05	0.0318	CbGeAlD
Celecoxib—ABCC4—tendon—psoriatic arthritis	1.46e-05	0.0317	CbGeAlD
Celecoxib—PTGS2—Spinal Cord Injury—TNF—psoriatic arthritis	1.46e-05	0.00152	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—NOS2—psoriatic arthritis	1.43e-05	0.00149	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—CRP—psoriatic arthritis	1.41e-05	0.00147	CbGpPWpGaD
Celecoxib—CA4—tendon—psoriatic arthritis	1.34e-05	0.0292	CbGeAlD
Celecoxib—PDPK1—Disease—NOS2—psoriatic arthritis	1.33e-05	0.00139	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—NOD2—psoriatic arthritis	1.16e-05	0.00121	CbGpPWpGaD
Celecoxib—CA2—tendon—psoriatic arthritis	1.11e-05	0.0242	CbGeAlD
Celecoxib—PTGS2—skin of body—psoriatic arthritis	1.08e-05	0.0235	CbGeAlD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	9.9e-06	0.00103	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—HLA-B—psoriatic arthritis	9.31e-06	0.000972	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CRP—psoriatic arthritis	8.23e-06	0.000859	CbGpPWpGaD
Celecoxib—PTGS2—tendon—psoriatic arthritis	8.23e-06	0.0179	CbGeAlD
Celecoxib—MAPK14—Immune System—HLA-DRB1—psoriatic arthritis	7.88e-06	0.000823	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—NOS2—psoriatic arthritis	7.4e-06	0.000772	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—TNF—psoriatic arthritis	7.25e-06	0.000756	CbGpPWpGaD
Celecoxib—PTGS2—Disease—NOS2—psoriatic arthritis	4.43e-06	0.000462	CbGpPWpGaD
